摘要
目的探讨血清125、CA199及AFP联合检测在诊断卵巢肿瘤中的临床价值。方法采用随机数字表法,随机选择2014年9月—2015年12月来该院就诊的70例卵巢恶性肿瘤患者作为观察组研究对象,选择同时期的30例良性卵巢肿瘤患者以及20名正常健康人作为对照组研究对象,探讨CA125、CA199、AFP联合检测在卵巢肿瘤诊断中的灵敏度和特异度。结果观察肿瘤患者组的CA125、CA199、AFP浓度分别为(162.7±16.6)、(112.8±24.4)、(19.3±2.6)ug/m L明显高于对照组(P<0.05),其水平随着肿瘤分期的进展呈现出正相关。联合应用明显高于单项血清标记物的灵敏度和特异度(P<0.05)。结论 CA125、CA199、AFP3种血清肿瘤标记物联合检测明显提高诊断卵巢肿瘤的准确性。
Objective To investigate the serum 125, CA199 and AFP joint clinical value in the diagnosis of ovarian tumors detected. Methods A random number table, select from September 2014 to Derember 2015 to our hospital 70 cases of ovarian cancer patients as the observation group studied 30 patients with benign ovarian tumors choose the same period and20 healthy as a control group who objects to study the CA125, CA199, AFP joint detection sensitivity and specificity in ovarian cancer diagnosis. Results CA125 tumor patient groups, CA199, AFP concentrations were（162.7 ± 16.6） u/m L,（112.8± 24.4） ug/m L,（19.3 ± 2.6） ug/m L was significantly higher（P 0.05）, the level of progress with the tumor stage showed a positive correlation. Combined with significantly higher serum markers of individual sensitivity and specificity（P 0.05）.Conclusion CA125, CA199, AFP Three Tumor Markers Combined Detection significantly improve the accuracy of diagnosis of ovarian cancer.
出处
《中外医疗》
2016年第26期28-29,32,共3页
China & Foreign Medical Treatment
